# Trial of High Intensity Focused Ultrasound (HIFU) for primary malignant bone tumours of the sacrum and coccyx

***HIFU unit, Churchill Hospital, Headington, Oxford , OX3 7LJ, UK***

Oxford University Hospitals NHS
NHS Trust

Dear colleagues,
I am delighted to announce the above trial is now open. We are looking for patients with primary malignant osseous tumours of the sacrococcygeal spine to enrol in this trial. Participants should be over 18yrs and willing to travel to Oxford on at least 5 occasions.



## Theory

High energy sound waves can be focused on a selected point, selectively causing coagulative necrosis in that area, leaving adjacent tissue unharmed. Using ultrasound guidance, tumours can be selectively ablated leaving normal tissues around the tumour intact. This approach has been used largely experimentally to treat prostate, renal cell carcinomas, amongst others.

## Trial

We wish to undertake a trial to assess whether HIFU has a positive role in the management of tumours such as sacral chordomas and sarcomas.
We propose to analyse patients': (1) radiological response to treatment, and (2) their functional outcome to treatment. The design of the trial is shown below.
I look forward to hearing from you!

Best wishes,
Stana Bojanic, Consultant Neurosurgeon.

**For further information or to make referrals please contact: Miss Stana Bojanic, Consultant Neurosurgeon, HIFU unit, Churchill Hospital, Headington, Oxford, OX3 7LJ.**
**Email: stana.bojanic@ouh.nhs.uk**

| | |
|---|---|
| Contact 1 | •Referral with relevant data<br>•Invitation letter with written information sent to patient and referring clinician |
| Contact 2 | •Patient travels to oxford for enrolment and clinical assessment |
| Contact 3 | •After cooling off period, patient travels to oxford to plan and receive treatment. |
| Contact 4 | •Day 2 (post treatment) patient assessed clinically for adverse response to treatment and discharged. Patients may require more than one cycle of treatment for large tumours. |
| Contact 5 | •After 6 weeks, patient travels to Oxford for radiological and clinical assessment of response to treatment. |
| Contact 6 | •At 6 months after treatment finishes, patient travels to Oxford for radiological and clinical assessment of response to treatment |
| Contact 7 | •After 1 year, patient travels to Oxford for radiological and clinical assessment of response to treatment, active participation ends |
| Contact 8 | •Patients' GPs or the referring specialist is contacted to assess survival (the patient or patient's relatives are NOT contacted directly) |

Date: 16/7/12
Version: 2.0
REC reference number: 12/SS/0144